Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 2/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531263 | 0.92 | FFAR1 (0.35) | FFAR1KAT6AKAT5AURKARPS6KB1 | |
| SCHEMBL2530502 | 0.91 | AURKA (0.32) | FFAR1KAT6AKAT5S1PR3AURKA | |
| SCHEMBL2526887 | 0.90 | NR1H4 (0.39) | FFAR1KAT6AKAT5S1PR3NR1H4 | |
| SCHEMBL2532739 | 0.88 | HTT (0.36) | FFAR1S1PR3FPR2KMT2A | |
| SCHEMBL2526892 | 0.88 | MAPT (0.38) | FFAR1KAT6AKAT5AURKARPS6KB1 | |
| SCHEMBL2525580 | 0.87 | CYP26A1 (0.32) | FFAR1AURKARPS6KB1GPR88 | |
| SCHEMBL2529616 | 0.87 | GPR88 (0.33) | KAT6AKAT5AURKARPS6KB1GPR88 | |
| SCHEMBL2531611 | 0.87 | KDM4E (0.39) | FFAR1AURKARPS6KB1KMT2A | |
| SCHEMBL2530772 | 0.87 | KMT2A (0.35) | FFAR1AURKARPS6KB1GPR88KMT2A | |
| SCHEMBL2524954 | 0.87 | AURKA (0.34) | FFAR1KAT6AKAT5S1PR3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039501-B2 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2011-10-18 | — | — | US | disclosed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | FFAR1 60/4885KAT6A 1834/4885KAT5 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.